Progress in the use of biochemical and biological markers for evaluation of rheumatoid arthritis

Journal of Clinical Laboratory Analysis

Volumn 14, Issue 6, 2000, Pages 305-313

  Nakamura, Robert M ^a  

^a SCRIPPS CLINIC   (United States)

Author keywords

Biochemical; Biological and genetic markers; Laboratory tests; Rheumatoid arthritis

Indexed keywords

ARTICLE; AUTOIMMUNITY; BONE TURNOVER; DIAGNOSTIC VALUE; DISEASE CLASSIFICATION; DISEASE MARKER; GENETIC MARKER; HUMAN; LABORATORY TEST; PATHOGENESIS; PATIENT MONITORING; RHEUMATOID ARTHRITIS;

ACUTE-PHASE PROTEINS; ANTIBODIES, ANTINUCLEAR; ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; BONE REMODELING; COLLAGEN; CYTOKINES; HUMANS; INTERMEDIATE FILAMENT PROTEINS; JOINTS; PROGNOSIS; RHEUMATOID FACTOR;

EID: 0033667582     PISSN: 08878013     EISSN: None     Source Type: Journal    
DOI: 10.1002/1098-2825(20001212)14:6<305::AID-JCLA10>3.0.CO;2-P     Document Type: Article

References (80)

1. The epidemiology of rheumatoid arthritis: A review. II. Incidence and diagnostic criteria
2. Etiology and pathogenesis of rheumatoid arthritis
3. Clinical features of rheumatoid arthritis
4. Rheumatoid arthritis
5. The effect of pregnancy on rheumatoid arthritis
6. 1958 Revision of diagnostic criteria for rheumatoid arthritis
7. Classification of rheumatoid arthritis
8. Pathogenesis of rheumatoid arthritis
9. Inhibition of the production and effects of interleukin-1 and tumor necrosis factor α in rheumatoid arthritis
10. Biologic agents and immunotherapy in rheumatoid arthritis
11. Soluble tumor necrosis factor receptor (p75) fusion protein (Enbrel) as a therapy for rheumatoid arthritis
12. Anti-tumor necrosis factor α monoclonal antibody therapy for rheumatoid arthritis
13. Interleukin-1 receptor antagonist
14. Pathways to gene therapy in rheumatoid arthritis
15. Gene therapy for rheumatic diseases
16. IL-10 as a therapeutic strategy in the treatment of rheumatoid arthritis
17. Oral tolerization as a treatment of rheumatoid arthritis
18. Selection and use of laboratory tests in the rheumatic diseases
19. Marker antibodies of rheumatoid arthritis: Diagnostic and pathogenetic implications
20. Established and new biochemical tools for diagnosis and monitoring of rheumatoid arthritis
21. The influence of HLA-DRAB1 genes on disease severity in rheumatoid arthritis
22. Correlation between disease phenotype and genetic heterogeneity in rheumatoid arthritis
23. Histocompatibility typing in the rheumatic diseases. Diagnostic and prognostic implications
24. Influence of the HLA-DRB1 locus on susceptibility and severity in rheumatoid arthritis
25. Genetic typing of patients with inflammatory arthritis at presentation can be used to predict outcome
26. Analysis of the candidate gene NRAMP1 in the first 61 ARC National Repository Families for Rheumatoid Arthritis
27. On the occurrence of a factor in human serum activating the specific agglutination of a sheep blood corpuscles
28. Rheumatoid factor
29. Rheumatoid factors
30. Predictive value of rheumatoid factor isotypes for radiological progression in patients with rheumatoid arthritis
31. Rheumatoid factor isotypes, disease activity and the outcome of rheumatoid arthritis
32. Combined elevation of IgM and IgA rheumatoid factor has high diagnostic specificity for rheumatoid arthritis
33. Combined elevation of IgM and IgA rheumatoid factor has high diagnostic specificity for rheumatoid arthritis
34. Clinical implications of IgA rheumatoid factor subclasses
35. What about IgA rheumatoid factor in rheumatoid arthritis?
36. Rheumatoid factor
37. Cryoglobulinemia: A clinical and laboratory study. II. Cryoglobulins with rheumatoid factor activity
38. IgG rheumatoid factor, complement and immune complexes in rheumatoid synovitis, and vasculitis: Comparative and serial studies during cytotoxic therapy
39. Antinuclear antibodies: Diagnostic markers for autoimmune diseases and probes for cell biology
40. Antinuclear antibodies (ANAs): Diagnostically specific immune markers and clues toward the understanding of systemic autoimmunity
41. Reaction of antibodies to rheumatoid arthritis nuclear antigen with a synthetic peptide corresponding to part of Epstein-Barr nuclear antigen 1
42. Characteristics of antinuclear antibodies in rheumatoid arthritis
43. Antinuclear antibodies
44. Reactivity of antinuclear antibodies with histones and other antigens in juvenile rheumatoid arthritis
45. Antihistone antibodies in antinuclear antibody-positive juvenile arthritis
46. Update on autoantibodies to intracellular antigens in systemic rheumatic diseases
47. The antiperinuclear factor and the so-called antikeratin antibodies are the same rheumatoid arthritis-specific autoantibodies
48. A new serum factor in patients with rheumatoid arthritis. The antiperinuclear factor
49. The antiperinuclear factor and antikeratin antibodies in rheumatoid arthritis
50. Antiperinuclear factor isotypes in rheumatoid arthritis
51. Antikeratin antibodies in rheumatoid arthritis
52. Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies
53. Laboratory evaluation of inflammation
54. Concordant message of different inflammatory markers in patients with rheumatoid arthritis
55. Rheumatoid arthritis exhibits reduced acute phase and enhanced constitutive serum amyloid A protein in synovial fluid relative to serum. A comparison with C-reactive protein
56. Analysis of changes in acute-phase plasma proteins in an acute inflammatory response and in rheumatoid arthritis using two-dimensional gel electrophoresis
57. The value of C-reactive protein measurement in rheumatoid arthritis
58. C-reactive protein and the acute phase response
59. Serological reactions in pneumonia with a non-protein somatic fraction of pneumococcus
60. Serum and synovial fluid levels of serum amyloid A protein and C-reactive protein in inflammatory and noninflammatory arthritis
61. Serum amyloid A protein induces production of matrix metalloproteinases by human synovial fibroblasts
62. Interleukin-6 in relation to other proinflammatory cytokines, chemotactic activity and neutrophil activation in rheumatoid synovial fluid
63. Interleukin 1 β, hand and foot bone mineral content, and the development of joint erosions in rheumatoid arthritis
64. Systemic cytokine measurements: Their role in monitoring the response to therapy in patients with rheumatoid arthritis
65. Increased IL-1 receptor antagonist (IL-1ra) production and decreased IL-iβ/1L-1ra ratio in mononuclear cells from rheumatoid patients
66. Anti-RA 33. A valuable serologic marker for early diagnosis of rheumatoid arthritis
67. Demonstration of a new antinuclear antibody (anti-RA 33) that is highly specific for rheumatoid arthritis
68. Purification and partial sequencing of the nuclear autoantigen RA33 shows that it is indistinguishable from the A2 protein of the heterogeneous nuclear ribonucleoprotein complex
69. Anti-RA33 autoantibodies may recognize epitopes in the N-terminal region of hnRNP-A2 (RA33)
70. Anti-RA 33 antinuclear autoantibody in rheumatoid arthritis and mixed connective tissue disease: Comparison with antikeratin and antiperinuclear antibodies
71. Clinical utility and serological connections of anti-RA33 antibodies in systemic lupus erythematosus
72. Measurement of serum hyaluronic acid in patients with rheumatoid arthritis: Correlation with disease activity
73. Serum hyaluronan as a disease marker
74. Cartilage and bone metabolism in RA. Differences between rapid and slow progression of disease identified by serum markers of cartilage metabolism
75. Knee joint synovial fluid content of aggrecan predicts knee/hip joint destruction in rheumatoid arthritis
76. A new biochemical marker for joint injury. Analysis of YKL-40 in serum and synovial fluid
77. Increased release of bone sialoprotein into synovial fluid reflects tissue destruction in rheumatoid arthritis
78. Urinary hydroxpyridinium cross-links of collagen in rheumatoid arthritis, relation to disease activity and effects of methylprednisolone
79. Increased type I collagen degradation correlates with disease severity in rheumatoid arthritis
80. Type I collagen degradation product in serum of patients with early rheumatoid arthritis: Relationship to disease activity and radiological progression in a 3-year follow-up